Join Growin Stock Community!

4d molecular therapeutics, inc.FDMT.US Overview

US StockHealthcare
(No presentation for FDMT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

FDMT AI Insights

FDMT Overall Performance

FDMT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

FDMT Recent Performance

-5.38%

4d molecular therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

FDMT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

FDMT Key Information

FDMT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

FDMT Profile

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Price of FDMT

FDMT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

FDMT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.10
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4599.37
PB Ratio
1.34
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-174314.17%
Revenue Growth (YoY)
605.88%
Profit Growth (YoY)
605.88%
3-Year Revenue Growth
-43.54%
3-Year Profit Growth
-43.54%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.10
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4599.37
PB Ratio
1.34
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-174314.17%
Revenue Growth (YoY)
605.88%
Profit Growth (YoY)
605.88%
3-Year Revenue Growth
-43.54%
3-Year Profit Growth
-43.54%

  • When is FDMT's latest earnings report released?

    The most recent financial report for 4d molecular therapeutics, inc. (FDMT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating FDMT's short-term business performance and financial health. For the latest updates on FDMT's earnings releases, visit this page regularly.

  • What is the operating profit of FDMT?

    According to the latest financial report, 4d molecular therapeutics, inc. (FDMT) reported an Operating Profit of -61.19M with an Operating Margin of -67,983.33% this period, representing a decline of 19.66% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is FDMT's revenue growth?

    In the latest financial report, 4d molecular therapeutics, inc. (FDMT) announced revenue of 90K, with a Year-Over-Year growth rate of 2,900%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does FDMT have?

    As of the end of the reporting period, 4d molecular therapeutics, inc. (FDMT) had total debt of 22.26M, with a debt ratio of 0.05. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does FDMT have?

    At the end of the period, 4d molecular therapeutics, inc. (FDMT) held Total Cash and Cash Equivalents of 48.56M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does FDMT go with three margins increasing?

    In the latest report, 4d molecular therapeutics, inc. (FDMT) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -67,983.33%%, and net margin of -63,195.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess FDMT's profit trajectory and future growth potential.

  • Is FDMT's EPS continuing to grow?

    According to the past four quarterly reports, 4d molecular therapeutics, inc. (FDMT)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of FDMT?

    4d molecular therapeutics, inc. (FDMT)'s Free Cash Flow (FCF) for the period is -46.41M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 48.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of FDMT?

    The latest valuation data shows 4d molecular therapeutics, inc. (FDMT) has a Price-To-Earnings (PE) ratio of -2.78 and a Price/Earnings-To-Growth (PEG) ratio of -0.7. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.